MA42249A - Traitement de carcinome de la ligne médiane nut - Google Patents

Traitement de carcinome de la ligne médiane nut

Info

Publication number
MA42249A
MA42249A MA042249A MA42249A MA42249A MA 42249 A MA42249 A MA 42249A MA 042249 A MA042249 A MA 042249A MA 42249 A MA42249 A MA 42249A MA 42249 A MA42249 A MA 42249A
Authority
MA
Morocco
Prior art keywords
median line
carcinoma treatment
line carcinoma
nut
nut median
Prior art date
Application number
MA042249A
Other languages
English (en)
Inventor
Michael H Kagey
Steven B Landau
Original Assignee
Tensha Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tensha Therapeutics Inc filed Critical Tensha Therapeutics Inc
Publication of MA42249A publication Critical patent/MA42249A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA042249A 2015-06-26 2016-06-24 Traitement de carcinome de la ligne médiane nut MA42249A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26

Publications (1)

Publication Number Publication Date
MA42249A true MA42249A (fr) 2018-05-02

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042249A MA42249A (fr) 2015-06-26 2016-06-24 Traitement de carcinome de la ligne médiane nut

Country Status (14)

Country Link
US (1) US20180193350A1 (fr)
EP (1) EP3314005A1 (fr)
JP (1) JP2018520124A (fr)
KR (1) KR20180035785A (fr)
CN (1) CN107787227A (fr)
AR (1) AR105124A1 (fr)
AU (1) AU2016283020A1 (fr)
BR (1) BR112017028178A2 (fr)
CA (1) CA2989313A1 (fr)
HK (1) HK1252062A1 (fr)
IL (1) IL256186A (fr)
MA (1) MA42249A (fr)
MX (1) MX2017016337A (fr)
WO (1) WO2016210275A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
CA2799403C (fr) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions et methodes de traitement de la leucemie
CA2929652A1 (fr) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Polytherapie pour le traitement du cancer utilisant des inhibiteurs de proteine a bromodomaine et a domaine extra-terminal (bet)
EP3110424A1 (fr) 2014-02-28 2017-01-04 Tensha Therapeutics, Inc. Traitement de troubles associés à l'hyperinsulinémie
SG11201703414VA (en) 2014-10-27 2017-05-30 Tensha Therapeutics Inc Bromodomain inhibitors
EP4629984A1 (fr) * 2022-12-06 2025-10-15 BioVentures, LLC Développement d'inhibiteurs puissants de hdac/brd4

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR101600634B1 (ko) * 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2564318T3 (es) 2009-11-05 2016-03-21 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2652304T3 (es) 2009-11-05 2018-02-01 Glaxosmithkline Llc Compuesto de benzodiacepina novedoso
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (fr) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Inhibiteurs de bromodomaines et leurs utilisations
WO2012151512A2 (fr) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromodomaines et leurs utilisations
EP2721031B1 (fr) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Inhibiteurs à bromodomaine et leurs utilisations
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP3110424A1 (fr) 2014-02-28 2017-01-04 Tensha Therapeutics, Inc. Traitement de troubles associés à l'hyperinsulinémie

Also Published As

Publication number Publication date
EP3314005A1 (fr) 2018-05-02
US20180193350A1 (en) 2018-07-12
CA2989313A1 (fr) 2016-12-29
AR105124A1 (es) 2017-09-06
CN107787227A (zh) 2018-03-09
BR112017028178A2 (en) 2018-08-28
HK1252062A1 (zh) 2019-05-10
JP2018520124A (ja) 2018-07-26
MX2017016337A (es) 2018-11-22
IL256186A (en) 2018-02-28
AU2016283020A1 (en) 2018-01-04
KR20180035785A (ko) 2018-04-06
WO2016210275A1 (fr) 2016-12-29

Similar Documents

Publication Publication Date Title
EP3388004A4 (fr) Instrument de traitement
EP3377068A4 (fr) Polythérapie comprenant des analogues de la quinolone tétracyclique pour le traitement du cancer
EP3227763C0 (fr) Souris réglable
PL3127502T3 (pl) Układ czyszczący
MA41449A (fr) Polythérapies pour le traitement de cancers
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3409744A4 (fr) Agent de traitement de surface
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
PL3197456T3 (pl) Leczenie nowotworów
EP3352586A4 (fr) Traitement nutritionnel anticancéreux
EP3375108A4 (fr) Traitement dewlan
MA45429A (fr) Polythérapie pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3431566A4 (fr) Agent de traitement de surface
MA47408A (fr) Traitement du cancer
IL256206A (en) Mct4 inhibitors for treating disease
EP3297102A4 (fr) Connecteur
EP3705545A4 (fr) Composition de traitement de surface
MA41123A (fr) Polythérapie pour le traitement du cancer
BR112018006551A2 (pt) conjunto de porca bipartida
HUE040167T2 (hu) Rákkezelés
DK3451818T3 (da) Forarbejdningsenhed
MA42249A (fr) Traitement de carcinome de la ligne médiane nut
FR3039368B1 (fr) Procede de traitement cosmetique
SI3188599T1 (sl) Zdravljenje na osnovi anamorelina